ReviewDiabetology & metabolic syndrome2026
Reported cardiovascular events and cardiometabolic risk markers with orforglipron and danuglipron in adults with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized trials.
Guanglan Zou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.